Study
| Open-label, multicenter, phase 2 study |
| Unresectable or metasatic ASPS |
| Atezolizumab 1200 mg in adults (n=49) or 15 mg/kg (1200 mg max) in pediatric pts (n=3) once q21 days |
Efficacy
| ORR: 37% [19 of 52 pts] |
| mDoR: 24.7 mos [4.1-55.8] |
| mPFS: 20.8 mos |
Safety
| Any grade AEs: Musculoskeletal pain (67%); fatigue (55%); rash (47%); cough (45%); nausea, headache, and hypertension (43% each). |
N Engl J Med 2023; 389:911-92
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
http://doi.org/10.1056/NEJMoa2303383
Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023
